Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market

Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is placed ninth on our list.

TheFly reported on February 6 that Piper Sandler raised its price target on TVTX to $38 from $35 and maintained a Neutral rating on the shares. The adjustment comes following several Q4 and full-year 2025 pre-announcements and ahead of the company’s upcoming Q4 report. The firm used this period to review and update its estimates for select commercial names, including Travere, which prompted the revised price target.

Earlier on February 3, BofA also raised its price target on Travere Therapeutics, Inc. (NASDAQ:TVTX) to $44 from $43 and gave it a Buy rating. The firm noted that, given the recent pre-announcements, the upcoming Q4 earnings report may not have the same impact as in previous years. The price target adjustment reflects BofA’s updated view of the company within its biopharma coverage ahead of the quarterly results.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is a U.S. biopharmaceutical company focused on innovative rare disease therapies, developing and commercializing novel treatments like FILSPARI and enzyme replacement candidates for unmet renal and metabolic conditions, and leveraging patient‑centric science and strategic collaborations to drive breakthrough care.

While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.